Clinical trials: Metastatic Brain Cancer
Brain Tumors, Metastatic Disease
Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
RATIONALE: Donepezil may help lessen confusion and fatigue and improve mood and quality of life in patients who have undergone radiation therapy for brain tumors.
- Trial name
- NCT00369785
- Testing
- donepezil hydrochloride
- Where
- 16 sites in United States
- Volunteers
- 198 people
- Sponsor
- Wake Forest University Health Sciences
Brain Metastases, Small Cell Lung Cancer
Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases
This research study is studying stereotactic radiation (focused/pinpoint radiation that targets each individual tumor but not the surrounding brain) instead of whole-brain radiation (radiation targeting the entire brain) as a…
- Trial name
- NCT03391362
- Testing
- Stereotactic Radiation
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Brigham and Women's Hospital
Brain Metastases
A Proof-of-principle Study of HBO-SRS for Brain Metastases
Patients with brain metastases who are candidates for treatment with stereotactic radiosurgery (SRS) are potential study participants.
- Trial name
- NCT01850563
- Testing
- Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Kidney Cancer, Melanoma (Skin)
Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Conditions
- Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer
- Trial name
- NCT00550654
- Testing
- questionnaire administration, 3-dimensional conformal radiation therapy, hypofractionated radiation therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Melanoma, Non-Small Cell Lung Cancer
MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
The purpose of this trial is to study the activity of MK-3475 in untreated brain metastases from melanoma or non-small cell lung cancer.
- Conditions
- Melanoma, Non-Small Cell Lung Cancer, Brain Metastases
- Trial name
- NCT02085070
- Testing
- MK-3475
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Yale University
Dementia, Chronic Disease
Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1)
The objective of this protocol is to test the effectiveness of a Jumpstart intervention on patient-centered outcomes for patients with chronic illness by ensuring that they receive care that is concordant with their goals over…
- Conditions
- Dementia, Chronic Disease, Neoplasm Metastasis, Lung Neoplasm
- Trial name
- PICSI-H (NCT04281784)
- Testing
- EHR-based Clinician Jumpstart
- Where
- 3 sites in United States
- Volunteers
- 2,512 people
- Sponsor
- University of Washington
Brain Metastases
Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases
Vorinostat in combination with radiation therapy can be administered safely and will be tolerated in patients with brain metastases, while providing an assessment of the anti-tumor activity of this combination.
- Trial name
- NCT00838929
- Testing
- Vorinostat, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Brain and Central Nervous System Tumors, Intraocular Melanoma
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00445965
- Testing
- DNA analysis, immunologic technique, pharmacological study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Lung Cancer, Brain Neoplasms
A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)
This was an open-label, multicenter, single-arm, Phase II trial of bevacizumab combined with first- or second-line therapy in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with previously treated…
- Trial name
- NCT00312728
- Testing
- bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents
- Volunteers
- 115 people
- Sponsor
- Genentech, Inc.
Brain Tumor, Central Nervous System Tumor
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
RATIONALE: Sodium thiosulfate may reduce or prevent hearing loss in young patients receiving cisplatin for cancer. It is not yet known whether sodium thiosulfate is more effective than no additional treatment in preventing…
- Conditions
- Brain Tumor, Central Nervous System Tumor, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
- Trial name
- NCT00716976
- Testing
- sodium thiosulfate, examination
- Where
- 76 sites in United States, Australia and 1 more
- Volunteers
- 131 people
- Sponsor
- Children's Oncology Group
Malignant Melanoma
A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases
This open-label study will assess the safety and efficacy of RO5185426 in previously treated metastatic melanoma patients with brain metastases.
- Trial name
- NCT01253564
- Testing
- RO5185426
- Where
- 2 sites in Switzerland
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Brain Metastases, Adult
Neoadjuvant Immunotherapy in Brain Metastases
The purpose of this phase 2 study is to assess the feasibility and efficacy of neoadjuvant immunotherapy in patients with previously untreated, surgically-resectable, solid tumor brain metastases.
- Trial name
- NCT04434560
- Testing
- Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sarah Sammons, MD
Brain Metastases From Breast Cancer
F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer
To estimate the presence of hypoxia in individual lesions after radiotherapy in patients with brain metastases from breast cancer as identified by F18 EF5 PET/CT imaging.
- Trial name
- NCT01985971
- Testing
- PET/CT Imaging
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Extensive Stage Lung Small Cell Carcinoma, Malignant Solid Neoplasm
Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
This phase I trial seeks to find out the best dose, possible benefits and/or side effects of entinostat in combination with atezolizumab, carboplatin and etoposide for the treatment of previously untreated aggressive lung cancer…
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT04631029
- Testing
- Atezolizumab, Carboplatin, Entinostat
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Brain Metastases
A Dose Escalation Trial of Five Fraction Stereotactic Radiation Therapy for Brain Metastases
This study looks at dose escalation for five fraction stereotactic radiotherapy for patients diagnosed with brain metastases with tumors 2.1-4.0 cm in diameter or 4.1-6.0 cm in diameter.
- Trial name
- RAD1705 (NCT03412812)
- Testing
- 6 Gy, 7 Gy, 8 Gy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Alabama at Birmingham
Breast Cancer
Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis
This research study is studying the combination of a drug called atezolizumab and a radiation procedure called stereotactic radiosurgery (SRS) as a possible treatment for triple-negative breast cancer that has spread to the…
- Trial name
- NCT03483012
- Testing
- Atezolizumab, Stereotactic radiosurgery (SRS)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Dana-Farber Cancer Institute
Melanoma
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
To assess the response of melanoma with brain metastases to ipilimumab treatment while maintaining acceptable tolerability.
- Trial name
- NCT00623766
- Testing
- Ipilimumab, Corticosteroid: Betamethasone, Corticosteroid: Dexamethasone
- Where
- 14 sites in United States
- Volunteers
- 99 people
- Sponsor
- Bristol-Myers Squibb
Non-small Cell Lung Cancer (NSCLC) With Brain Metastases
GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)
The purpose of this study is to assess the efficacy, safety, and tolerability of GRN1005 in patients with brain metastases from non-small cell lung cancer (NSCLC).
- Trial name
- GRABM-L (NCT01497665)
- Testing
- GRN1005
- Where
- 10 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- Angiochem Inc
HER-2 Positive Breast Cancer, Metastatic Malignant Neoplasm to Brain
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Evaluate the safety and tolerability and determine the maximum tolerated dose (MTD) of the combination of tesevatinib and trastuzumab in subjects with HER2-positive metastatic breast cancer
- Trial name
- NCT02154529
- Testing
- Tesevatinib, Trastuzumab
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Kadmon Corporation, LLC
Anaplastic Astrocytoma, Glioblastoma
Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
In this multinational Phase III study the efficacy and safety of 10 µM AP 12009 is compared to standard chemotherapy (temozolomide or BCNU or CCNU) in adult patients with confirmed recurrent or refractory anaplastic astrocytoma…
- Trial name
- SAPPHIRE (NCT00761280)
- Testing
- trabedersen, temozolomide, Drug delivery system for administration of AP 12009
- Where
- 68 sites in United States, Argentina and 14 more
- Volunteers
- 27 people
- Sponsor
- Isarna Therapeutics GmbH